TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Healios KK ( (JP:4593) ) has shared an update.
Healios K.K. has announced the termination of its business and capital alliance with Nikon Corporation, initially formed to promote regenerative medicine commercialization. The decision follows a strategic reassessment by both companies, leading them to pursue independent paths. Healios plans to expand its operations as a Contract Development and Manufacturing Organization (CDMO) in 2025, focusing on regenerative and cellular medicine, with no expected impact on its 2025 financial results.
The most recent analyst rating on (JP:4593) stock is a Hold with a Yen476.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
More about Healios KK
HEALIOS K.K. is a leading clinical stage biotechnology company in Japan, specializing in regenerative medicine using stem cells. It focuses on developing new therapies for diseases lacking effective treatments, with proprietary platforms utilizing somatic and induced pluripotent stem cells. The company is advancing products like invimestrocel for conditions such as ischemic stroke and ARDS, and is working on gene-edited NK cell treatments for solid tumors.
Average Trading Volume: 7,401,978
Technical Sentiment Signal: Hold
Current Market Cap: Yen57.59B
For detailed information about 4593 stock, go to TipRanks’ Stock Analysis page.